ImmuCell Corporation ICCC
- Market cap
- $90.6M
- P/E
- 117×
Follow ICCC
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.76 | 5.00 | 6.38 | 4.70 | 3.70 | 5.73 | 5.98 | 4.26 | 3.34 | 4.28 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 8.29 | 9.25 | 9.30 | 8.28 | 8.13 | 13.20 | 10.96 | 7.84 | 5.82 | 7.60 |
High Price
|
|||
| 45 | 47 | 51 | 54 | 61 | 67 | 74 | 79 | 75 | 73 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 10 | 10 | 11 | 14 | 15 | 19 | 19 | 17 | 26 | 28 |
Revenue
|
|||
| 56.80% | 50.06% | 47.28% | 49.11% | 44.73% | 44.98% | 41.19% | 22.15% | 29.97% | 41.40% |
Gross Margin
|
|||
| 1 | 0 | (2) | (1) | (1) | 0 | (2) | (6) | (2) | (1) |
EBT
|
|||
| 7.95% | (4.20%) | (16.93%) | (9.24%) | (6.73%) | (0.36%) | (13.39%) | (33.02%) | (8.10%) | (3.72%) |
EBT Margin
|
|||
| 1 | 0 | (2) | (1) | (1) | 0 | (2) | (6) | (2) | (1) |
Net Income
|
|||
| 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 |
Depreciation
|
|||
| 2.26 | 2.11 | 2.00 | 2.01 | 2.13 | 2.53 | 2.40 | 2.26 | 3.24 | 3.06 |
Revenue/Sh
|
|||
| 0.12 | (0.03) | (0.42) | (0.19) | (0.14) | (0.01) | (0.32) | (0.75) | (0.26) | (0.12) |
Earnings/Sh
|
|||
| (0.05) | 0.24 | (0.07) | 0.03 | 0.18 | 0.13 | (0.20) | (0.60) | 0.04 | 0.27 |
Cash Flow/Sh
|
|||
| (0.84) | (3.58) | (0.32) | (0.14) | (0.56) | (0.34) | (0.51) | (0.24) | (0.06) | (0.13) |
Capex/Sh
|
|||
| (0.89) | (3.34) | (0.39) | (0.10) | (0.38) | (0.22) | (0.71) | (0.85) | (0.01) | 0.14 |
Free CF/Sh
|
|||
| 4.67 | 4.77 | 3.96 | 4.25 | 3.92 | 4.29 | 3.92 | 3.23 | 3.37 | 3.00 |
Book Value/Sh
|
|||
| 4 | 5 | 5 | 7 | 7 | 8 | 8 | 8 | 8 | 9 |
Shares
|
|||
| 43.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 2.63 | 3.92 | 3.52 | 2.56 | 2.80 | 3.16 | 2.70 | 2.22 | 1.59 | 2.01 |
PS Ratio
|
|||
| 1.28 | 1.73 | 1.78 | 1.21 | 1.52 | 1.86 | 1.65 | 1.55 | 1.53 | 2.05 |
PB Ratio
|
|||
| 1.84 | 4.42 | 4.18 | 2.53 | 2.90 | 3.10 | 2.94 | 2.85 | 1.84 | 2.20 |
EV/Sales
|
|||
| (4.64) | (2.79) | (21.33) | (49.11) | (16.40) | (36.41) | (9.92) | (7.58) | (472.81) | 48.22 |
EV/FCF
|
|||
| 0 | 1 | 0 | 0 | 1 | 1 | (2) | (5) | 0 | 2 |
Op' Cash Flow
|
|||
| (4) | (18) | (2) | (1) | (4) | (3) | (4) | (2) | 0 | (1) |
Capex
|
|||
| (4) | (17) | (2) | (1) | (3) | (2) | (6) | (7) | 0 | 1 |
FCF
|
|||
| 12 | 5 | 4 | 11 | 10 | 14 | 11 | 7 | 11 | 13 |
Working Cap'
|
|||
| 3 | 9 | 10 | 8 | 9 | 9 | 10 | 12 | 11 | 9 |
Total Debt
|
|||
| (8) | 5 | 7 | 0 | 2 | (1) | 4 | 11 | 7 | 5 |
Net Debt
|
|||
| 20 | 24 | 22 | 29 | 28 | 33 | 30 | 25 | 28 | 27 |
Sh' Equity
|
|||
| 2.59% | (0.57%) | (6.93%) | (3.63%) | (2.59%) | (0.18%) | (5.58%) | (13.03%) | (4.85%) | (2.37%) |
ROA
|
|||
| 4.59% | (0.53%) | (3.12%) | (2.08%) | (2.89%) | 0.51% | (4.13%) | (9.98%) | (2.99%) | 3.19% |
ROIC
|
|||
| 3.35% | (0.78%) | (10.24%) | (5.11%) | (3.57%) | (0.26%) | (7.92%) | (20.86%) | (8.21%) | (3.81%) |
ROE
|
|||
ImmuCell Corporation peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CGTX Cognition Therapeutics, Inc. | $90.7M | 0.0× | Compare |
| ACRV Acrivon Therapeutics, Inc. | $90.9M | 0.0× | Compare |
| VXRT VAXART, INC. | $92.4M | 2.8× | Compare |
| RLYB Rallybio Corporation | $88.2M | 2.1× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PTHS Pelthos Therapeutics Inc. | $85.8M | 0.0× | Compare |
| ATRA Atara Biotherapeutics, Inc. | $85.7M | 0.0× | Compare |
| ANIX ANIXA BIOSCIENCES INC | $96.6M | 0.0× | Compare |
| NRXS Neuraxis, Inc. | $97.3M | 0.0× | Compare |
ImmuCell Corporation (ICCC) key facts
- ImmuCell Corporation (ICCC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- ImmuCell Corporation’s revenue for fiscal 2025 (year ended December 2025) was $27.6 million, up 4.34% from fiscal 2024.
- ImmuCell Corporation reported a net loss of $1.0 million, or a loss of $0.12 per share, for fiscal 2025.
- As of September 25, 2026, ICCC traded at $9.93, a market capitalization of $90.6 million.
- At that price the stock trades at 117× trailing-twelve-month earnings and 2.9× sales.
- Return on equity was −3.81% and debt-to-equity 0.26.
ImmuCell Corporation (ICCC) Latest News
20 Aug
ImmuCell (ICCC) held its Q2 2026 earnings call, covering financial results, operations and outlook. Quarterly earnings call supplies performance data and guidance that can shift short-term investor views.
14 Aug
ImmuCell Corp posted record net income and gained market share in Q2 2026. Record net income and market share gains indicate stronger financial results and competitive gains that can shift company trajectory.
ImmuCell held its Q2 earnings call, covering financial results, product performance, and operational updates. Earnings call delivers quarterly updates on finances and operations with moderate short-term market influence.
ImmuCell Corporation held its Q2 2026 earnings call covering financial results and business outlook. Q2 2026 earnings figures can moderately shift ImmuCell Corporation's near-term valuation and sentiment.
13 Aug
ImmuCell Corporation (ICCC) released unaudited financial results for the quarter ended June 30, 2026. Quarterly financial results offer direct data on ImmuCell's revenue, profitability and operational trends.
10 Jul
ImmuCell Corporation reports strong preliminary Q2 sales driven by U.S. demand. Strong preliminary sales indicate improved revenue outlook likely to lift near-term investor sentiment.
9 Jul
ImmuCell Corporation reported 12% higher product sales in Q2 2026 and 21% higher sales for the first six months of 2026 from preliminary unaudited figures. Reported sales growth directly signals stronger near-term revenue that can lift investor views on financial results.
15 May
ImmuCell Corp posted record Q1 2026 revenue and outlined strategic growth plans in its earnings call. Record revenue and new growth initiatives signal major positive shifts in performance and investor outlook.
ImmuCell Corporation released highlights from its Q1 earnings call, covering financial results, operational updates, and future outlook for the biotechnology firm focused on animal health products. Q1 earnings call highlights reveal quarterly financial performance and strategic updates that moderately affect investor sentiment and short-term stock trajectory.
ImmuCell Corporation held its Q1 2026 earnings call covering quarterly financial results, operational updates and forward guidance. Quarterly earnings release and call directly disclose financial metrics and outlook that move near-term stock valuation.
14 May
ImmuCell Corporation announced unaudited financial results for the quarter ended March 31, 2026. Unaudited quarterly financial results moderately influence financial performance and investor sentiment.
13 Apr
ImmuCell Corporation appoints Dr. Gilles Guillemette and Dr. Anthony DiMarco to its Board to bolster innovation strategy and transitions to a smaller board composed entirely of independent directors. Board appointments of innovation experts and shift to independent directors represent major strategic governance changes poised to enhance innovation and investor confidence.
8 Apr
ImmuCell Corporation announces a 28.4% increase in product sales for Q1 2026, based on preliminary, unaudited results. 28.4% sales growth in Q1 indicates significant positive momentum for ImmuCell's financial performance and investor sentiment.
6 Mar
ImmuCell Corporation (ICCC) Q4 2025 earnings call highlights navigating growth opportunities amid operational and market challenges. Earnings highlights indicate moderate influence from growth strategies offset by challenges on financial performance and trajectory.
ImmuCell Corporation's 2025 net loss narrowed year-over-year, driven by higher sales and improved margins. Narrower net loss from sales growth and margin expansion moderately boosts financial performance and investor sentiment.
5 Mar
ImmuCell Corporation (ICCC) released Q4 2025 earnings call summary detailing financial results, operational updates, and future outlook. Q4 earnings call summaries disclose financial performance and guidance that significantly shape investor sentiment and stock trajectory.
ImmuCell Corporation's Q4 earnings call highlighted financial results, product pipeline progress including Tri-Solfen and NisinRx advancements, revenue growth challenges, and optimistic 2024 outlook amid debt management. Q4 earnings highlights reveal moderate financial and operational updates influencing near-term performance without transformative shifts.
4 Mar
ImmuCell Corporation announced unaudited financial results for the year ended December 31, 2025. Annual financial results announcements significantly influence stock performance and investor sentiment.
15 Jan
ImmuCell Corporation is navigating a healthcare landscape shaped by niche focus and regulatory challenges. The company is poised to leverage its specialized products in the veterinary sector, particularly in the prevention of calf scours, amidst evolving regulations that impact market dynamics. As healthcare firms adapt to these changes, ImmuCell's strategic positioning may enhance its competitive edge and market performance. Regulatory changes and niche focus are likely to significantly impact ImmuCell's strategic direction and market positioning.
12 Jan
ImmuCell Corporation (NASDAQ: ICCC) has seen a 25% increase in stock value over the past year, reflecting positive investor sentiment and market performance. The company's focus on developing innovative products for the animal health sector appears to be resonating well with investors, contributing to this growth. Analysts suggest that continued advancements and strategic initiatives may further enhance ImmuCell's market position. The 25% stock increase indicates moderate investor confidence, but it does not signal a transformative change in the company's trajectory.
9 Jan
ImmuCell Corporation reported its Q4 earnings, highlighting significant growth in revenue driven by increased sales of its flagship product, First Defense. The company also discussed ongoing research and development efforts aimed at expanding its product line and improving operational efficiencies. Management expressed optimism about future market opportunities and outlined strategic initiatives to enhance shareholder value. Overall, the earnings call reflected a positive outlook for the company's performance in the upcoming quarters. The earnings call indicates significant growth and strategic initiatives that could alter the company's trajectory and investor sentiment.
8 Jan
ImmuCell Corporation announced preliminary, unaudited sales results for the fourth quarter and full year of 2025, indicating a significant increase in sales compared to previous periods. The company highlighted strong demand for its products, which contributed to the positive financial performance. These results reflect the effectiveness of ImmuCell's strategies and market positioning in the veterinary pharmaceutical sector. The substantial increase in sales suggests a significant impact on future performance and investor sentiment.
7 Jan
ImmuCell Corporation will hold a conference call with investors to discuss a strategic change in focus. The company aims to provide insights into its new direction and how it plans to adapt to evolving market conditions. A strategic change in focus could significantly impact the company's future trajectory and investor sentiment.
24 Dec
ImmuCell Corporation announced a strategic focus on its First Defense® product line after receiving an FDA Incomplete Letter regarding its Re-Tain® product. The company plans to prioritize resources and efforts towards First Defense®, which is aimed at improving the health of newborn animals, while addressing the feedback from the FDA for Re-Tain® to ensure compliance and future approval. The strategic shift towards First Defense® and the regulatory challenges with Re-Tain® are likely to significantly impact the company's future performance and market positioning.
4 Dec
ImmuCell Corporation is experiencing growth driven by its two key products aimed at improving cattle health. The company's innovative solutions are gaining traction in the market, positioning it favorably against competitors. This dual-product strategy is expected to enhance revenue streams and strengthen its market presence in the livestock industry. The introduction of two significant products is likely to have a substantial impact on ImmuCell's market position and financial performance.
24 Nov
ImmuCell Corporation (ICCC) reported its Q3 2025 earnings, highlighting strategic initiatives to navigate ongoing challenges in the market. The company emphasized its focus on product development and operational efficiency to enhance performance. Despite facing obstacles, management expressed optimism about future growth prospects and the potential impact of new product launches. The earnings call provided insights into the company's financial health and strategic direction, aiming to reassure investors amid a competitive landscape. Significant strategic initiatives and product developments are expected to influence the company's future performance and investor sentiment.
13 Nov
ImmuCell Corporation reported its unaudited financial results for the quarter ending September 30, 2025. The company highlighted key metrics, including revenue growth and operational developments, reflecting its ongoing commitment to advancing its product pipeline and market presence. Management expressed optimism about future prospects and strategic initiatives aimed at enhancing shareholder value. The financial results indicate moderate growth and operational progress, which may influence investor sentiment and future performance.
4 Nov
ImmuCell Corporation has announced the onboarding of a new CEO, Dr. Michael J. McGowan, who will also serve as the President. The company is undergoing related management changes, including the appointment of a new Chief Financial Officer, Dr. John D. H. Houghton. These leadership transitions are part of ImmuCell's strategy to enhance its operational capabilities and drive growth in the veterinary pharmaceutical market. Leadership changes at the executive level can significantly influence the company's strategic direction and market performance.
1 Nov
ImmuCell Corporation (ICCC) has experienced recent price fluctuations that may not be supported by its underlying fundamentals. The company's financial performance and operational metrics suggest weaknesses that could be influencing investor sentiment and market perception. Analysts are questioning whether the stock's movement reflects genuine growth potential or is merely a reaction to market speculation. As the company navigates its challenges, the sustainability of its price increases remains uncertain. Weak fundamentals may moderately influence investor sentiment and financial performance.
7 Oct
ImmuCell Corporation announced preliminary, unaudited sales results for the third quarter of 2025, indicating a significant increase in sales compared to the previous year. The company attributed this growth to strong demand for its products and successful marketing strategies. Further details on financial performance and future projections are expected in the upcoming official report. The significant increase in sales suggests a strong market position and potential for future growth.